Grant: Master's Award: Canada Graduate Scholarships
University of Alberta
$17,500.00
Development of novel vasopressor therapy during neonatal resuscitation
EF 2022-23
Résumé
Most newborns will successfully transition from fetal to neonatal life without external support; however, despite resuscitative efforts, approximately 1 million of these newborns will die every year. Epinephrine is the only drug recommended for use in neonatal resuscitation; yet its optimal timing, route, and dosage remains unestablished, and it can have severe side effects in newborns. Therefore, researchers are interested if another drug, vasopressin, may be a better alternative. The literature is divided, and so the objectives of this research are to determine whether vasopressin is a better drug than epinephrine during resuscitation, and which route of administration is most effective at achieving return of spontaneous circulation (ROSC). It is hypothesized that high-dose vasopressin will produce better results (less time to ROSC) than epinephrine, while also limiting adverse effects, and that intravenous administration is the most effective route at delivering vasopressin to the central nervous system. I will examine the optimal doses of epinephrine and vasopressin in newborn asphyxiated piglets, as well as three specific routes of administration: intravenous (IV) and intraosseous (IO) placement, in addition to endotracheal intubation. Real-time blood flow will be measured and collected to be analyzed using enzyme-linked immunosorbent assay (ELISA), whose results will show which route of administration is most effective at distributing the drugs within the central venous system. Through this approach, I will identify the optimal doses and routes administration of vasopressin and epinephrine for neonatal resuscitation. This data has the potential to create new vasopressor recommendations to best guide healthcare workers in neonatal resuscitation.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486145
Name
Ramsie Marwa
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of novel vasopressor therapy during neonatal resuscitation
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adrenaline; Cardiac Arrest; Epinephrine; Neonatal; Resuscitation; Vasopressin; Vasopressor
Abstract
Most newborns will successfully transition from fetal to neonatal life without external support; however, despite resuscitative efforts, approximately 1 million of these newborns will die every year. Epinephrine is the only drug recommended for use in neonatal resuscitation; yet its optimal timing, route, and dosage remains unestablished, and it can have severe side effects in newborns. Therefore, researchers are interested if another drug, vasopressin, may be a better alternative. The literature is divided, and so the objectives of this research are to determine whether vasopressin is a better drug than epinephrine during resuscitation, and which route of administration is most effective at achieving return of spontaneous circulation (ROSC). It is hypothesized that high-dose vasopressin will produce better results (less time to ROSC) than epinephrine, while also limiting adverse effects, and that intravenous administration is the most effective route at delivering vasopressin to the central nervous system. I will examine the optimal doses of epinephrine and vasopressin in newborn asphyxiated piglets, as well as three specific routes of administration: intravenous (IV) and intraosseous (IO) placement, in addition to endotracheal intubation. Real-time blood flow will be measured and collected to be analyzed using enzyme-linked immunosorbent assay (ELISA), whose results will show which route of administration is most effective at distributing the drugs within the central venous system. Through this approach, I will identify the optimal doses and routes administration of vasopressin and epinephrine for neonatal resuscitation. This data has the potential to create new vasopressor recommendations to best guide healthcare workers in neonatal resuscitation.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ramsie, Marwa
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~